Kornimate/medical-research-clean huggingface dataset:
genetic predisposition to severe forms of covid-19 (sars-cov2 infection)

Conditions: Covid19

Summary: the main objective of this part of the project is to identify the germline genetic factors which discriminate the benign and severe forms of sars-cov2 (covid-19) infection in the context of the ongoing sars-cov2 (hcovid-19) epidemic. the scientific arguments of the project are described in appendix. we hypothesize that pathogenic variants in genes coding for crucial factors involved in the host pathogen interaction could explain the susceptibility of some patients to severe disease, even in the absence of comorbidities. the challenge is to identify those of the genetic factors who may be related respiratory distress and potentially further death. based on our previous experience in sarcoidosis, a multifactorial disease predisposing to opportunistic infections, we will focus particularly the regulation of apoptosis and autophagy, immune response to viral infection, and endoplasmic reticulum stress response (er stress) which is closely linked to apoptosis. genetic defects in such pathways may decrease the clearance of viral particles and induces the progressive invasion by sars-cov2 and destruction of lung parenchyma. our strategy will be similar to that described in our previous studies on sarcoidosis, recently published. we will combine a comparative genotype analysis by whole exome sequencing (wes) of benign and severe forms of sars-cov2 infection through clinical subgroups defined by the infectious diseases experts and a bioinformatics analysis of the functional networks identified by the panel of genes sharing pathogenic variants and discriminating the severe forms of the diseases. wes data will be carefully analyzed and related to all the intracellular physiological process and also the functional pathways involved in host-pathogen interaction: viral targets on the cell surface and downstream signaling, viral genomic rna replication and translation, production and release of new viral particles. finally, our main objectives are the definition of a gene panel more specifically related to severe forms of infection and the characterization of defective pathways involved in pejorative forms of sars-cov2 disease in order to identify putative therapeutic targets.


Eligibility criteria:
inclusion criteria: * patients affected by covid-10 age: 18-70 (values included) without any co morbidities (analysis of the clinical files in our hospital) without any regular treatments exclusion criteria: * below 18yr and higher than 70yr old * with comorbidities - ex: diabetes, obesity, hypertension, ischemic heart, neurological disorders, autoinflammatory / autoimmune diseases ... * not agreeing the protocol (absence of informed consent)

Keywords: coronavirus sars cov2 covid-19 genetics predisposition critical care
ac/dc study: acidification test in patients with chronic kidney disease and healthy controls

Conditions: Chronic Kidney Disease stage4

Summary: in this study the effect of an acute acid load on the intrarenal renin angiotensin-system is evaluated in patients with chronic kidney disease and healthy controls

metabolic acidosis is one of the metabolic complications of chronic kidney disease (ckd). correction of metabolic acidosis in ckd has been shown to prevent further loss of kidney function over time. currently, a clinical trial (the bic-study, mec-2013-332) is conducted in which patients with ckd and metabolic acidosis receive sodium bicarbonate, sodium chloride, or no treatment (time control) to address the hypothesis that the beneficial effects of acidosis correction are mediated through inhibition of the intrarenal renin-angiotensin system (ras). it is unknown, however, if and how acute changes in acid-base status affect the intrarenal ras during ckd. in the present study it is hypothesized that an acute acid load increases the activity of the intrarenal ras, and that this response is exaggerated in patients with ckd compared with healthy controls.

Eligibility criteria:
patients with ckd: * male or female adults (≥18 years) * chronic kidney disease stage 4 (egfr: 15-30 ml/min/1.73 m2, calculated using the ckd-epi equation) healthy controls: * healthy male or female adults (≥ 18 years) * normal kidney function (egfr \> 90 ml/min/1.73 m2, calculated using the ckd-epi equation) exclusion criteria: * ckd patients * plasma bicarbonate level \< 20.0 mmol/l * serum potassium \>5.5 mmol/l * sodium bicarbonate use in the month preceding the test * heart failure (nyha iii or iv) * liver cirrhosis (child pugh b or c) * blood pressure \>140/90 mmhg despite the use of 3 different anti-hypertensive drugs * kidney transplantation * use of calcineurin inhibitors (these immunosuppressive drugs affect acid-base balance) * known urea cycle disorder * alcoholism or drug use * pregnancy * current use of antibiotics, nsaids or alkalizing drugs (sodium-bicarbonate, citric acid, potassium citrate, acetazolamide) * inability to adhere to the study protocol (due to language barrier or intellectual disability) healthy controls: * egfr \< 90 ml/min/1.73 m2 (calculated using the ckd-epi equation) * plasma bicarbonate \< 20 mmol/l * history of, or drugs for, diabetes mellitus * history of chronic diarrheal disease * ileostomy/colostomy * known urea cycle disorder * alcoholism or drug use * pregnancy * current use of antibiotics, antihypertensive drugs, nsaids or alkalizing drugs (sodium-bicarbonate, citric acid, potassium citrate, acetazolamide) * inability to adhere to the study protocol (due to language barrier or intellectual disability)
si-6603 versus placebo in patients with lumbar disc herniation

Conditions: Lumbar Vertebra Hernia

Summary: the purpose of this study is to determine whether si-6603 is effective in the treatment of lumbar disc herniation.


Eligibility criteria:
inclusion criteria: * patients with lumbar disc herniation (l4-l5 or l5-s1) as assessed by mri and clinical symptoms corresponding to position of the impaired nerve root * patients assessed as positive in the slr test * patients with sciatica in either lower leg * patients with no improvement from pharmacotherapy or concomitant treatment with drug and nerve block exclusion criteria: * patients who have 2 or more lumbar disc herniations as assessed by mri * patients with "extrusion-type" or "sequestration-type" herniation in whom a rupture into the posterior longitudinal ligament is identified by mri * patients who have received nerve block within 3 weeks before screening * patients who have undergone lumbar operation, chemonucleolysis, or percutaneous nucleotomy

Keywords: chemonucleolysis lumbar vertebrae hernia
fertility after therapy with intensive lymphoma in young women: lnh-03 1b, lnh-03 2b, lnh-07 3b, gained follow-up

Conditions: DLBCL - Diffuse Large B Cell Lymphoma

Summary: the fertile study is a retrospective cohort study evaluating fertility after intensive treatment with rchop14/rchop21 or acvbp in young patients with diffuse large b-cell lymphoma treated in clinical trials conducted by the lysa group and still alive several years after the end of the trial.

the fertile study is a retrospective cohort study evaluating fertility after intensive treatment with rchop14/rchop21 or acvbp in young patients (≤ 38 years) with diffuse large b-cell lymphoma treated in 4 clinical trials conducted by the lysa group and still alive several years after the end of the trial. chemotherapy treatments used to treat diffuse large b-cell lymphoma in women of childbearing age may cause loss of fertility. there are few studies dedicated specifically to women treated for non-hodgkin's lymphoma, particularly in the context of intensive chop-based regimens (r-chop14/r-chop21/r-acvbp). these studies do not provide any details on the type of treatment and the clinical characteristics of the patients. it is in this context that we propose the fertile study. this study is based on the collection and reuse of data already available in the lnh03-1b, lnh03-2b, lnh07-3b and gained clinical trials such as the age of the patients, the treatments, the diagnosis. the results of hormonal assessments and fertility tests (endovaginal ultrasound) will also be consulted in the medical file. in addition, a questionnaire concerning fertility will be proposed by the physician-investigator.

Eligibility criteria:
inclusion criteria: 1. the subjects are women 2. participation in one of the following clinical trials: lnh 03 1b or lnh 03 2b or lnh 07 3b or gained 3. age at initial diagnosis between 18 years and 38 years inclusive, which has allowed their inclusion in the clinical trial 4. treated with r-acvbp or r-chop14/r-chop21 in these clinical trials 5. no relapse of their diffuse large b-cell lymphoma 6. possible use of stem cell transplantation during clinical trials 7. subjects are still alive today exclusion criteria: 1. subjects died 2. subjects lost to follow-up
lifestyle coaching for fatigue mitigation in emergency medicine residents

Conditions: Lifestyle, Healthy; Sleepiness; Alertness; Shift-Work Related Sleep Disturbance; Work Related Stress; Self Efficacy; Self-Compassion

Summary: the purpose of this study is to determine whether personalized lifestyle coaching minimizes the negative impact of circadian disruption on performance and recovery in emergency medicine physician trainees during night shifts.

the goal of this study is to examine whether a brief personalized fatigue-mitigation lifestyle coaching (pfmlc) for emergency medicine residents on overnight shifts would minimize the negative effects of circadian rhythm disruptions on performance and recovery compared to those who receive one-time passive information on lifestyle practices.

Eligibility criteria:
inclusion criteria: * stanford health care (shc) emergency medicine residents (pgy 1 to 4) * scheduled to work at least 3 consecutive overnight shifts at shc emergency department. exclusion criteria: * non-stanford health care (shc) emergency medicine residents * stanford health care (shc) emergency medicine residents who are not rotating in stanford emergency medicine department

Keywords: physician well-being occupational well-being resident well-being physician coaching lifestyle coaching night shifts
the influence of combined oral contraception on the development and progression of chronic venous diseases

Conditions: Chronic Venous Diseases

Summary: investigation of the influence of combined oral contraception on the development and progression of chronic venous diseases


Eligibility criteria:
inclusion criteria: 1. the investigators consistently include patients who have been prescribed hormonal tablets for contraception, namely 1) cocs with bioidentical estrogen; 2) cocs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) cocs with ethinyl estradiol 20mkg according to the scheme 21 + 7. 2. clinical class c0-1 according to ceap; 2) able to come for checkups every 3 months; 3) the presence of informed consent. exclusion criteria: 1. age up to 45 years; 2. a history of surgical treatment of veins of the lower extremities; 3. clinical class c2 and higher according to ceap; 4. history of dvt or pe; 5. aplasia or angio-dysplasia of deep veins; 6. restriction of mobility; 7. arterial insufficiency; 8. oncological diseases.
seasonal trends in pneumococcal carriage in copd patients

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: patients suffering from chronic obstructive pulmonary disease (copd) commonly get exacerbations of their illness which have many potential triggers including infection. the most common cause of lung infection/pneumonia is an organism named streptococcus pneumoniae. in ireland a 13-valent pneumococcal conjugated vaccine (pcv-13) was recently introduced into the childhood vaccination programme. this study aims to investigate the carriage rate of s. pneumoniae in copd patients over one year and to determine if isolates of s. pneumoniae found within the copd population would be covered by the pcv-13 vaccine.

this study aims to determine the potential contribution of s. pneumoniae to the morbidity of patients with copd in ireland and if the pcv-13 has potential for reducing infective exacerbations in this cohort. a group of 150 copd patients are being monitored at quarterly intervals over one year. at each study visit patients report changes to copd-related medication, recent hospitalisations and exacerbations and provide a sputum sample (or pharyngeal swab if not possible) which is assessed for the presence of s. pneumoniae. the specific objectives of the study are: 1. to monitor the carriage rate of pneumococci in a cohort of irish patients with copd during and outside periods of acute exacerbation over a one year period. 2. to assess the copd exacerbation rate amongst this group of patients. 3. to monitor changes in the proportion of patients positive for pneumococci carriage over a full season and to document those patients intermittently or permanently colonised. 4. to characterise s. pneumoniae isolates carried by copd patients in terms of their genetic evolution, comparison with strains in other countries, and antimicrobial susceptibility. 5. to assess the proportion of colonised copd patients that would be covered by current and future pneumococcal vaccines.

Eligibility criteria:
inclusion criteria: * over 18 years of age. * have a clinical diagnosis of copd. * have a forced expiratory volume at one second/forced vital capacity (fev1/fvc) ratio \< 80%. exclusion criteria: * patients too unwell.

Keywords: chronic obstructive pulmonary disease (copd) streptococcus pneumoniae pneumonia pneumococcal conjugate vaccine-13 (pcv-13) pneumococcal polysaccharide vaccine-23 (ppv-23) pneumococcal vaccine
study of oxaliplatin/5-fu/leucovorin plus vatalanib versus oxaliplatin/5-fu/leucovorin in patients with previously treated metastatic colorectal cancer

Conditions: Colorectal Neoplasms; Colonic Neoplasms; Rectal Neoplasms

Summary: the purpose of this study is to compare treatment with oxaliplatin/5-fu/leucovorin plus vatalanib versus oxaliplatin/5-fu/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose disease has worsened after treatment with irinotecan.


Eligibility criteria:
inclusion criteria * confirmed adenocarcinoma of the colon or rectum in patients with metastatic disease * one prior chemotherapy regimen with irinotecan and 5fu * evidence of progressive disease within 6 months after last dose of irinotecan * who performance status of 0, 1, or 2 * measurable tumors * adequate hematologic status, liver and kidney function * life expectancy greater than 12 weeks * written informed consent obtained exclusion criteria * history or presence of central nervous system disease * patients with a history of another primary cancer within 5 years * prior chemotherapy within 3 weeks before entry to study * major surgery within 4 weeks or minor surgery within 2 weeks before entry to study * investigational drugs within 4 weeks before entry to study * prior therapy with oxaliplatin * peripheral neuropathy with functional impairment * female patients who are pregnant or breast feeding * any severe or uncontrolled medical condition which could prevent participation in study * chronic kidney disease * acute or chronic liver disease * patients taking coumadin

Keywords: colorectal cancer oxaliplatin vegf inhibitor vatalanib ptk787 colon cancer colorectal carcinoma rectal cancer colorectal tumor
the effectiveness of oral health in improving dysphagia of patients after stroke of swallowing function and oral health quality of life

Conditions: Swallowing Disorders; Stroke

Summary: the prevalence of chewing dysphagia in the domestic rehabilitation department ward was about 53.61%.nasal tube retention of about 31%, due to nasogastric tube feeding, often overlooked oral hygiene, easy to cause respiratory tract infection. at the same time, oral hygiene will also affect the effectiveness of swallowing treatment, is worthy of attention to health problems.


Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of first stroke with nasal tube retention 2. language therapist providing swallowing treatment 3. caregiver providing oral care to patients exclusion criteria: 1. oral cancer 2. head and neck cancer

Keywords: stroke , swallowing function ,oral health quality of life
efficacy of mouthwashes in reducing severe acute respiratory syndrome coronavirus 2 (sars-cov-2) viral load in the saliva

Conditions: Covid19; Coronavirus

Summary: this is a single-blind, parallel-group, randomized pilot study designed to evaluate and compare the efficacy of 3 different mouthwashes containing 0.2% chlorhexidine digluconate, 1.5% hydroxide peroxide or cetylpyridinium chloride in reducing severe acute respiratory syndrome coronavirus 2 (sars-cov-2) viral load in the saliva of covid-19 positive patients at different time-points. a convenient sample of up to 40 covid-19 positive patients diagnosed via test and/or presenting covid-19 clinical symptoms will be identified in the inpatients and/or outpatient clinics at the newham university hospital and at the royal london hospital, barts health national health service (nhs) trust, united kingdom (uk). the study will consist of one visit. unstimulated saliva samples will be collected from all covid-19 positive patients before and at 30 minutes, 1, 2, and 3 hours after mouth rinsing (group 1-3 ) or no rinsing (group 4). viral load analysis of saliva samples in the different time-points will be then assessed by reverse transcription quantitative pcr (rt- qpcr).


Eligibility criteria:
all of the following criteria must be fulfilled for inclusion: * patients must have willingness to read and sign a copy of informed consent form. * males and females, ≥ 18 years old. * covid-19 positive patients confirmed via any diagnostic test and/or presented with covid-19 clinical symptoms at point of consent. exclusion criteria for patients patients presenting with any of the following will not be included in the trial: * known pre-existing chronic mucosal lesions e.g. lichen planus or other oropharyngeal lesions, reported by patient or recorded in the existing patient' medical notes; * patients currently intubated or not capable of mouth rinse or spit; * history of head and neck radiotherapy or chemotherapy; * self-reported xerostomia; * known allergy or hypersensitivity to chlorhexidine digluconate or one of the mouthwashes constituents; * other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial; * inability to comply with study protocol.

Keywords: mouthwash chlorhexidine digluconate hydroxide peroxide cetylpyridinium chloride viral load sars-cov-2
study of recombinant coagulation factor ix fc fusion protein, biib029, in previously treated pediatric participants with hemophilia b

Conditions: Hemophilia B

Summary: the primary objective of the study is to evaluate the safety of recombinant human coagulation factor ix fc fusion protein (rfixfc) in previously treated pediatric subjects with hemophilia b. secondary objectives of this study in this study population are as follows: to evaluate the efficacy of rfixfc for prevention and treatment of bleeding episodes; to evaluate and assess the pharmacokinetics (pk) of rfixfc; to evaluate rfixfc consumption for prevention and treatment of bleeding episodes

at the baseline visit (28 ± 7 days prior to day 1), participants receive a single iv injection of prestudy fix over 10 (±5) minutes in the clinic under medical supervision at a dose of 50 iu/kg. a washout period with no fix treatment is required prior to administration of prestudy fix and prior to rfixfc. a pk assessment is done with prestudy fix and also done with rfixfc on day 1. after completing the pk assessments, participants begin weekly prophylactic treatment with rfixfc for approximately 50 weeks, to obtain 50 eds. one ed is defined as a 24-hour period in which a participant received 1 or more doses of rfixfc, with the time of the first injection of rfixfc defined as the start of the ed.

Eligibility criteria:
key inclusion criteria: * severe hemophilia b defined as ≤ 2 iu/dl (≤ 2%) endogenous fix * male \< 12 years and weight ≥ 13 kg * history of at least 50 documented prior exposure days to fix * no history of, or currently detectable, inhibitor key exclusion criteria: * other coagulation disorders in addition to hemophilia b * history of anaphylaxis associated with any fix or iv immunoglobulin administration note: other protocol defined inclusion/ exclusion criteria may apply.
powered exoskeleton for the treatment of elbow spasticity

Conditions: Muscle Spasticity; Stroke

Summary: this is a phase-ii clinical study to assess whether intense passive mobilization of the elbow during the early stage is effective in preventing spasticity from occurring at a later stage. a group of subacute stroke patients was treated with the device named neuroexos elbow module (neem) on a daily basis, in addition to traditional physical therapy. the outcome was assessed in terms of (i) system safety, (ii) system usability and (iii) treatment efficacy. investigators expected that intense therapy performed in the sub-acute phase following the stroke would be effective in preventing elbow spasticity from occurring at a later stage (i.e. 3-4 months after the stroke), the latter being quantified by means of the modified ashworth scale (mas). similarly to other phase-ii studies in the field of post-stroke rehabilitation, the present study will include only one group of patients. as a secondary objective, similarly to other studies with robot-assisted therapy, investigators wiil test the ability of this system to be used for assessing rehabilitation outcome. investigators will introduce novel evaluation metrics based on the kinematics and kinetics variables recorded by the neem and compared them with mas values.


Eligibility criteria:
inclusion criteria: 1. upper limb spasticity due to neurological impairment; 2. cognitive abilities sufficient for understanding instructions; 3. absence of severe pain assessed as visual analogic score (vas) \< 4 (range 0-10). exclusion criteria: 1. unstable general clinical conditions; 2. unability to keep sitting posture; 3. tendon retractions limiting upper limb joints range of motion.

Keywords: robotics upper extremity